https://www.selleckchem.com/pr....oducts/Azacitidine(V
007), respiratory failure (p = 0.01, and increased mortality (p = 0.02). Receipt of a SOT primarily accounted for increased severity, respiratory failure, and mortality in immunosuppressed patients. SOT recipients had an 18-fold higher annual incidence for blastomycosis than the general population. The rate of disseminated blastomycosis was similar among NIC, SOT, and non-SOT IC. Relapse rates were low (5.3 - 7.7%). CONCLUSIONS Immunosuppression had implications regarding the acuity, severity, and respiratory failure. The
Like
Comment
Share
